• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

259.00 +0.67 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 162,519
Open 258.87
Bid (Size) 259.00 (1,100)
Ask (Size) 259.30 (300)
Prev. Close 258.33
Today's Range 255.61 - 259.89
52wk Range 122.80 - 298.30
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗
April 07, 2026
The biotech is off to a pretty decent start. 
Via The Motley Fool
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
March 23, 2026
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+4.9%
+4.9%
1 Month
+1.6%
+1.6%
3 Month
-0.9%
-0.9%
6 Month
+42.7%
+42.7%
1 Year
+61.2%
+61.2%

More News

Read More
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
Krystal Biotech Inc (NASDAQ:KRYS) Reports Q4 2025 Earnings Beat and Key Pipeline Advancements ↗
February 17, 2026
Via Chartmill
Topics Earnings
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
March 16, 2026
Via The Motley Fool
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
February 22, 2026
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
February 22, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗
February 17, 2026
Via Stocktwits
Topics Artificial Intelligence
News headline image
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗
February 17, 2026
Via The Motley Fool
News headline image
Got $300? 2 Biotech Stocks to Buy and Hold Forever ↗
February 16, 2026
Via The Motley Fool
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
February 13, 2026
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
January 25, 2026
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
January 24, 2026
Via The Motley Fool
News headline image
Why a Fund Placed a $13 Million Bet on Ambarella Stock Before a 20% Post-Earnings Drop ↗
December 19, 2025
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Is IPG Photonics Stock a Buy as One Fund Builds a $9 Million Stake in the Firm? ↗
December 19, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund Has an $8.5 Million Bet on Five9 Despite a 50% One-Year Stock Collapse ↗
December 19, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
December 03, 2025
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
December 03, 2025
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
December 03, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today ↗
November 12, 2025
Via Benzinga
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
November 10, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
What's Driving the Market Sentiment Around Krystal Biotech Inc? ↗
November 06, 2025
Via Benzinga

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 259.00
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 04/10/26 04:00 PM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 5.75B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap